Inhibikase Therapeutics
IKT
IKT
13 hedge funds and large institutions have $598K invested in Inhibikase Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
78% less capital invested
Capital invested by funds: $2.69M → $598K (-$2.1M)
Holders
13
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$19.5K | |
| 2 | +$4.64K | |
| 3 | +$2.07K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$300 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$207 |
Top Sellers
| 1 | -$432K | |
| 2 | -$49.8K | |
| 3 | -$41K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.2K |
| 5 |
Edgewood Management
Greenwich,
Connecticut
|
-$1 |